SCHEMBL2803750

SCHEMBL2803750

O=c1nc(NO)c(I)cn1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYGM P11217 3/20 0.55
LMNA P02545 3/20 0.53
MTOR P42345 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TP53 P04637 2/20 0.53
THRB P10828 1/20 0.53
MDM2 Q00987 1/20 0.53
NCOA1 Q15788 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
GMNN O75496 1/20 0.53
NFKB1 P19838 1/20 0.53
DNMT1 P26358 1/20 0.53
THPO P40225 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
BLM P54132 1/20 0.53
HBB P68871 1/20 0.53
PMP22 Q01453 1/20 0.53
ADK P55263 3/20 0.51
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15010715 0.86 LMNA (0.54) PYGMLMNAMTORALDH1A1TP53
SCHEMBL15010716 0.86 LMNA (0.54) PYGMLMNAMTORALDH1A1TP53
SCHEMBL16741022 0.86 PYGM (0.51) PYGMLMNAMTORALDH1A1TP53
SCHEMBL16741020 0.86 PYGM (0.51) PYGMLMNAMTORALDH1A1TP53
SCHEMBL20668770 0.85 LMNA (0.53) PYGMLMNAMTORALDH1A1TP53
SCHEMBL20668768 0.85 LMNA (0.53) PYGMLMNAMTORALDH1A1TP53
SCHEMBL20668805 0.85 LMNA (0.53) PYGMLMNAMTORALDH1A1TP53
SCHEMBL20668807 0.85 LMNA (0.53) PYGMLMNAMTORALDH1A1TP53
SCHEMBL2800037 0.85 PYGM (0.55) PYGMLMNAMTORALDH1A1TP53
SCHEMBL2803646 0.85 PYGM (0.55) PYGMLMNAMTORALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2018-10-16 US disclosed
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION GILEAD SCIENCES, INC. (US) 2014-02-27 US disclosed
EP-2251015-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation Pharmasset, Inc. (US) 2010-11-17 EP disclosed
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation PHARMASSET, INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION SLC29A1, PNP, SLC29A2 PYGM 89/4885LMNA 1019/4885MTOR 3027/4885
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, SLC29A2, PNP PYGM 99/4885LMNA 821/4885MTOR 3796/4885
US-20030087873-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, PNP, SLC29A2 PYGM 72/4885LMNA 1076/4885MTOR 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.